12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xalkori crizotinib: Phase III data

Top-line data from the open-label, international Phase III PROFILE 1007 trial in about 318 patients with previously treated ALK-positive advanced NSCLC showed that twice-daily 250 mg oral Xalkori met the primary endpoint of median PFS vs. investigator's choice of pemetrexed or docetaxel. Adverse events observed with Xalkori and chemotherapy were generally consistent with their...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >